Achieving and maintaining cognitive vitality with aging

被引:180
作者
Fillit, HM
Butler, RN
O'Connell, AW
Albert, MS
Birren, JE
Cotman, CW
Greenough, WT
Gold, PE
Kramer, AF
Kuller, LH
Perls, TT
Sahagan, BG
Tully, T
机构
[1] Inst Study Aging Inc, New York, NY 10153 USA
[2] Mt Sinai Med Ctr, Dept Geriatr Med & Neurobiol, New York, NY 10029 USA
[3] Int Longev Ctr, New York, NY USA
[4] Massachusetts Gen Hosp, Dept Psychiat & Neurol, Boston, MA 02114 USA
[5] Univ Calif Los Angeles, Ctr Aging, Los Angeles, CA USA
[6] Univ Calif Irvine, Dept Neurol Biol & Behav, Irvine, CA USA
[7] Univ Illinois, Beckman Inst, Urbana, IL 61801 USA
[8] Univ Illinois, Dept Psychol & Neurosci Program, Urbana, IL 61801 USA
[9] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA
[10] Boston Med Ctr, Boston, MA USA
[11] Pfizer Inc, Groton, CT 06340 USA
[12] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA
关键词
D O I
10.4065/77.7.681
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cognitive vitality is essential to quality of life and survival in old age. With normal aging, cognitive changes such as slowed speed of processing are common, but there is substantial interindividual, variability, and cognitive decline is clearly not inevitable. In this review, we focus on recent research investigating the association of various lifestyle factors and medical comorbidities with cognitive aging. Most of these factors are potentially modifiable or manageable, and some are protective. For example, animal and human studies suggest that lifelong learning, mental and physical exercise, continuing social engagement, stress reduction, and proper nutrition may be important factors in promoting cognitive vitality in aging. Manageable medical comorbidities, such as diabetes, hypertension, and hyperlipidemia, also contribute to cognitive decline in older persons. Other comorbidities such as smoking and excess alcohol intake may contribute to cognitive decline, and avoiding these activities may promote cognitive vitality in aging. Various therapeutics, including cognitive enhancers and protective agents such as antioxidants and anti-inflammatories, may eventually prove useful as adjuncts for the prevention and treatment of cognitive decline with aging. The data presented in this review should interest physicians who provide preventive care management to middle-aged and older individuals who seek to maintain cognitive vitality with aging.
引用
收藏
页码:681 / 696
页数:16
相关论文
共 242 条
[1]   A randomized controlled trial of prednisone in Alzheimer's disease [J].
Aisen, PS ;
Davis, KL ;
Berg, JD ;
Schafer, K ;
Campbell, K ;
Thomas, RG ;
Weiner, MF ;
Farlow, MR ;
Sano, M ;
Grundman, M ;
Thal, LJ .
NEUROLOGY, 2000, 54 (03) :588-593
[2]   Predictors of cognitive change in older persons: MacArthur studies of successful aging [J].
Albert, MS ;
Savage, CR ;
Blazer, D ;
Jones, K ;
Berkman, L ;
Seeman, T ;
Rowe, JW .
PSYCHOLOGY AND AGING, 1995, 10 (04) :578-589
[3]   Androgen-behavior correlations in hypogonadal men and eugonadal men .1. Mood and response to auditory sexual stimuli [J].
Alexander, GM ;
Swerdloff, RS ;
Wang, C ;
Davidson, T ;
McDonald, V ;
Steiner, B ;
Hines, M .
HORMONES AND BEHAVIOR, 1997, 31 (02) :110-119
[4]   Androgen-behavior correlations in hypogonadal men and eugonadal men - II. Cognitive abilities [J].
Alexander, GM ;
Swerdloff, RS ;
Wang, C ;
Davidson, T ;
McDonald, V ;
Steiner, B ;
Hines, M .
HORMONES AND BEHAVIOR, 1998, 33 (02) :85-94
[5]  
Alzheimers Assoc, 1998, NEUROBIOL AGING, V19, P109
[6]  
[Anonymous], 1996, GUID CLIN PREV SERV
[7]  
ARAI H, 1997, ALZHEIMERS RES, V3, P211
[8]   Ultrasonographic assessment of carotid wall characteristics and cognitive functions in a community sample of 59- to 71-year-olds [J].
Auperin, A ;
Berr, C ;
BonithonKopp, C ;
Touboul, PJ ;
Ruelland, I ;
Ducimetiere, P ;
Alperovitch, A .
STROKE, 1996, 27 (08) :1290-1295
[9]   Potential role of muscarinic agonists in Alzheimer's disease [J].
Avery, EE ;
Baker, LD ;
Asthana, S .
DRUGS & AGING, 1997, 11 (06) :450-459
[10]   N-acetylserotonin, melatonin and their derivatives improve cognition and protect against β-amyloid-induced neurotoxicity [J].
Bachurin, S ;
Oxenkrug, G ;
Lermontova, N ;
Afanasiev, A ;
Beznosko, B ;
Vankin, G ;
Shevtzova, E ;
Mukhina, T ;
Serkova, T .
NEUROPROTECTIVE AGENTS: FOURTH INTERNATIONAL CONFERENCE, 1999, 890 :155-166